查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1615476

HIV 臨床試驗市場：按階段、試驗設計、介入類型、市場參與企業、贊助商 – 2025-2030 年全球預測

HIV Clinical Trials Market by Phase (Phase I, Phase II, Phase III), Study Design (Expanded Access Studies, Interventional Studies, Observational Studies), Type of Intervention, Participant, Sponsor - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，HIV臨床試驗市場價值為11.5億美元，預計到2024年將達到12.3億美元，複合年成長率為7.20%，到2030年預計將達到18.8億美元。

HIV 臨床試驗市場包括旨在開發、測試和改善 HIV 及相關疾病的治療方法和預防的各種試驗。這些試驗的範圍包括評估新的抗逆轉錄病毒、疫苗和臨床實驗治療的安全性和有效性，以改善患者的治療結果，並朝著潛在的治癒和功能緩解邁進。全球愛滋病毒流行、不斷變化的病毒格局和抗藥性模式凸顯了愛滋病毒臨床試驗的必要性，這需要不斷創新和調整治療方法。 HIV 臨床試驗開發跨越各個階段，從藥物開發和概念驗證研究的早期階段到專注於比較長期安全性和有效性的後期研究。最終的使用範圍擴展到尋求實施循證治療通訊協定的藥物開發商、醫療保健提供者、研究機構和政策制定者。

主要市場統計
基準年[2023] 11.5億美元
預計年份 [2024] 12.3億美元
預測年份 [2030] 18.8億美元
複合年成長率（%） 7.20%

該市場受到生物技術進步、公共和私人資金增加以及對愛滋病毒認知不斷提高等因素的支持。潛在的發展機會包括利用基因組資料開發個人化醫療方法以及探索新型疫苗平台和長效抗逆轉錄病毒藥物。然而，高昂的研究成本、監管障礙、臨床實驗人群的倫理考量以及潛在的招募困難等限制因素構成了重大障礙。創新可以在諸如用於試驗資料分析的機器學習、使用虛擬或分散方法納入以患者為中心的試驗設計以及探索潛在的協同效應聯合治療等領域發展。

關鍵的市場成長要素包括人口變化，特別是在高發病率地區，以及強調治療和預防的綜合護理模式的興起。公司可以透過投資與學術機構和患者倡導團體的夥伴關係來增強信任並推動臨床試驗的註冊，從而受益。總體而言，動態變化的市場動態需要不斷的研究和策略調整，以有效地利用技術進步和患者需求。

市場動態：揭示快速發展的愛滋病毒臨床試驗市場的關鍵市場洞察

供需的動態交互作用正在改變愛滋病毒臨床試驗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球愛滋病發病率不斷上升
    • 製藥公司和非營利組織增加對愛滋病毒臨床試驗的投資
  • 市場限制因素
    • 與 HIV 臨床試驗和相關研發成本相關的高成本
  • 市場機會
    • 政府增加愛滋病毒治療和藥物的核准
    • HIV臨床試驗技術和解決方案的進展
  • 市場挑戰
    • HIV 臨床試驗制定的複雜性

波特五力：引領愛滋病毒臨床試驗市場的策略工具

波特的五力架構是了解愛滋病毒臨床試驗市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解 HIV 臨床試驗市場的外部影響

外部宏觀環境因素在塑造愛滋病毒臨床試驗市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助企業預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解 HIV 臨床試驗市場的競爭格局

HIV 臨床試驗市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣 HIV 臨床試驗市場供應商的績效評估

FPNV定位矩陣是評估HIV臨床試驗市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃愛滋病毒臨床試驗市場的成功之路

HIV 臨床試驗市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地感染愛滋病的人數不斷增加
      • 製藥公司和非營利組織增加了對愛滋病毒臨床試驗的投資活動
    • 抑制因素
      • HIV 臨床試驗和相關研發成本相關的高成本
    • 機會
      • 政府增加愛滋病毒治療和藥物的核准
      • HIV臨床試驗技術和解決方案的進展
    • 任務
      • HIV 臨床試驗藥物處方的複雜性
  • 市場區隔分析
    • 階段：增加 III 期臨床試驗的數量，以提供新的治療方法
    • 贊助：增加製藥和生物製藥公司的贊助，以提高藥品的商業性可用性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 HIV 臨床試驗市場：依階段、研究設計、介入類型、市場階段

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第7章 HIV 臨床試驗市場：階段、試驗設計、介入類型、市場研究設計

  • 擴大訪問研究
  • 干預研究
  • 觀察性研究

第8章 HIV 臨床試驗市場：依階段、試驗設計、介入類型、市場介入類型

  • 藥物治療
  • 疫苗

第9章 HIV 臨床試驗市場：依階段、研究設計、介入類型和市場參與企業

  • 成人
  • 小兒科
  • 孕婦

第 10 章 HIV 臨床試驗市場：階段、試驗設計、介入類型、市場贊助商

  • 非營利組織
  • 製藥和生物製藥公司

第11章美洲愛滋病毒臨床試驗市場：階段、試驗設計、介入類型、市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區愛滋病毒臨床試驗市場：階段、研究設計、介入類型、市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 13 章：歐洲、中東和非洲 HIV 臨床試驗市場：階段、研究設計、介入類型和市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 愛滋病臨床試驗小組的臨床試驗旨在提高愛滋病毒治療的有效性和安全性
    • 研究表明，在不同人群中，注射卡博特韋在預防愛滋病毒方面優於口服 PrEP。
    • ReiThera、Ragon Institute 和 IAVI 開始創新 T 細胞 HIV 疫苗 HIVconsvX 的 I 期試驗
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • American Gene Technologies Inc
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Emcure Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-7C50F273957B

The HIV Clinical Trials Market was valued at USD 1.15 billion in 2023, expected to reach USD 1.23 billion in 2024, and is projected to grow at a CAGR of 7.20%, to USD 1.88 billion by 2030.

The HIV clinical trials market encompasses a wide array of studies aiming to develop, test, and refine treatments and preventive measures for HIV and associated conditions. The scope of these trials includes evaluating the safety and efficacy of new antiretroviral drugs, vaccines, and investigational therapies, intending to improve patient outcomes and advance towards a potential cure or functional remission. The necessity for HIV clinical trials is underscored by the ongoing global HIV prevalence, changing viral landscapes, and resistance patterns, which necessitate continuous innovation and adaptation in therapeutic approaches. Applications of HIV clinical trials span across various phases, from early-stage drug development and proof-of-concept studies to late-stage trials focusing on long-term safety and comparative effectiveness. The end-use scope extends to pharmaceutical developers, healthcare providers, research institutions, and policy-makers aiming to implement evidence-based treatment protocols.

KEY MARKET STATISTICS
Base Year [2023] USD 1.15 billion
Estimated Year [2024] USD 1.23 billion
Forecast Year [2030] USD 1.88 billion
CAGR (%) 7.20%

The market is bolstered by factors such as advancements in biotechnology, increasing public and private funding, and heightened awareness of HIV. Potential opportunities include developing personalized medicine approaches leveraging genomic data, as well as exploring novel vaccine platforms and long-acting antiretrovirals. However, limitations such as high research costs, regulatory hurdles, ethical considerations regarding trial populations, and potential recruitment challenges pose significant barriers. Innovation can thrive in areas like machine learning for trial data analysis, incorporation of patient-centric trial designs utilizing virtual or decentralized methods, and exploring combination therapies that may provide synergistic benefits.

Key market growth factors include demographic shifts, particularly in high-incidence regions, and the emergence of integrative care models that emphasize both treatment and prevention. Businesses can benefit by investing in partnerships with academic institutions and patient advocacy groups to foster trust and enhance enrollment in trials. Overall, the dynamic and evolving nature of the HIV clinical trials market demands continual research and strategy adaption to harness technological advancements and patient needs effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HIV Clinical Trials Market

The HIV Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of AIDS disease worldwide
    • Growing investment activities by pharmaceutical and non-profit organizations for HIV clinical trials
  • Market Restraints
    • High costs associated with HIV clinical trials and associated research & development costs
  • Market Opportunities
    • Rising governmental approvals for HIV drugs and medications
    • Advancements in HIV clinical trial technologies and solutions
  • Market Challenges
    • Complexities in drug formulation of HIV clinical trials

Porter's Five Forces: A Strategic Tool for Navigating the HIV Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HIV Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HIV Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HIV Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HIV Clinical Trials Market

A detailed market share analysis in the HIV Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HIV Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HIV Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the HIV Clinical Trials Market

A strategic analysis of the HIV Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the HIV Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., American Gene Technologies Inc, AstraZeneca PLC, Bayer AG, BioNTech SE, Boehringer Ingelheim International GmbH, Cipla Ltd., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the HIV Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Study Design, market is studied across Expanded Access Studies, Interventional Studies, and Observational Studies.
  • Based on Type of Intervention, market is studied across Drug Therapy and Vaccines.
  • Based on Participant, market is studied across Adults, Pediatric, and Pregnant Women.
  • Based on Sponsor, market is studied across Non Profit Organizations and Pharmaceutical & Biopharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of AIDS disease worldwide
      • 5.1.1.2. Growing investment activities by pharmaceutical and non-profit organizations for HIV clinical trials
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with HIV clinical trials and associated research & development costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising governmental approvals for HIV drugs and medications
      • 5.1.3.2. Advancements in HIV clinical trial technologies and solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in drug formulation of HIV clinical trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Phase: Increasing the number of phase III clinical trials to make the new treatments available
    • 5.2.2. Sponsor: Increasing sponsorship from pharmaceutical & biopharmaceutical companies to enhance commercial availability of medications
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. HIV Clinical Trials Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III
  • 6.5. Phase IV

7. HIV Clinical Trials Market, by Study Design

  • 7.1. Introduction
  • 7.2. Expanded Access Studies
  • 7.3. Interventional Studies
  • 7.4. Observational Studies

8. HIV Clinical Trials Market, by Type of Intervention

  • 8.1. Introduction
  • 8.2. Drug Therapy
  • 8.3. Vaccines

9. HIV Clinical Trials Market, by Participant

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Pediatric
  • 9.4. Pregnant Women

10. HIV Clinical Trials Market, by Sponsor

  • 10.1. Introduction
  • 10.2. Non Profit Organizations
  • 10.3. Pharmaceutical & Biopharmaceutical Companies

11. Americas HIV Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific HIV Clinical Trials Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa HIV Clinical Trials Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Clinical Trial by AIDS Clinical Trials Group Seeks to Enhance HIV Treatment Efficacy and Safety
    • 14.3.2. Study Shows Injectable Cabotegravir Surpasses Oral PrEP in HIV Prevention Across Diverse Groups
    • 14.3.3. ReiThera, Ragon Institute, and IAVI Launch Phase I Trials for Innovative T-Cell HIV Vaccine, HIVconsvX
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. American Gene Technologies Inc
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. BioNTech SE
  • 6. Boehringer Ingelheim International GmbH
  • 7. Cipla Ltd.
  • 8. CSL Limited
  • 9. Daiichi Sankyo Company, Limited
  • 10. Eli Lilly and Company
  • 11. Emcure Pharmaceuticals Ltd.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline plc
  • 15. Janssen Pharmaceuticals, Inc.
  • 16. Johnson & Johnson Services, Inc.
  • 17. Merck & Co., Inc.
  • 18. Moderna, Inc.
  • 19. Mylan N.V.
  • 20. Novartis AG
  • 21. Pfizer Inc.
  • 22. Regeneron Pharmaceuticals, Inc.
  • 23. Sanofi S.A.
  • 24. Sun Pharmaceutical Industries Limited
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. HIV CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. HIV CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HIV CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HIV CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON PROFIT ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 235. HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023